LOS
ANGELES, July 30, 2024 /PRNewswire/ -- Nervonik, a
medical device startup focusing on neurotechnology approaches to
peripheral nerve stimulation, has received approval to conduct a
first-in-human feasibility study utilizing its proprietary
technology. The focus will be on chronic pain of peripheral nerve
origin, although the novel technology will eventually be utilized
for a variety of medical indications.
Dr. Aydin Babakhani, PhD, founder
and CEO of Nervonik, stated, "This is a big step for Nervonik and
the evolution of peripheral nerve stimulation in the treatment of
chronic pain". Peripheral nerve stimulation is a rapidly growing
market, and the advancement of technology in this space being
propelled by Nervonik will help provide solutions for chronic pain
patients.
Dr. Timothy Deer, President &
CEO, of The Spine and Nerve Centers of the Virginias, commented
that, "Nervonik is advancing our ability to treat chronic pain
patients with their novel technology. This is a key area for
innovation in the field of chronic pain, and we are excited to be
conducting this study". Dr. Deer also presented a paper at the 2024
American Society of Pain and Neuroscience (ASPN) annual conference
on the technology Nervonik has been developing.
Enrollment in the study is anticipated to begin later in the
3rd quarter of 2024 with presentation of results
following.
CONTACT: Info@Nervonik.com
View original
content:https://www.prnewswire.com/news-releases/nervonik-receives-regulatory-approval-to-start-first-in-human-study-with-novel-peripheral-nerve-stimulation-technology-for-chronic-pain-302208201.html
SOURCE Nervonik Inc.